Oncology - Kisqali and Kisqali Femara Co-Pack Prior Authorization Policy
Cigna prior authorization policy defining medical necessity criteria, approval durations, and covered indications for Kisqali (ribociclib) and Kisqali Femara Co-Pack (ribociclib + letrozole) across FDA-approved and selected evidence-supported uses (early breast cancer adjuvant, recurrent/metastatic breast cancer in women and men, and endometrial cancer).
Requirement that patient is receiving a GnRH analog was changed to only apply if Kisqali is used in combination with anastrozole, exemestane, or letrozole.
Endometrial cancer indication (Kisqali + letrozole) was added as 'Other Uses with Supportive Evidence'.
Early breast cancer (adjuvant) indication added with 3-year approval duration.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.